Research programme: cancer therapies - SalubrisBio
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator SalubrisBio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 29 Sep 2020 Cancer therapies is available for licensing as of 29 Sep 2020 (http://salubrisbio.com/Portal/Partner.aspx)
- 29 Sep 2020 SalubrisBio plans to files an IND application for Cancer (SalubrisBio pipeline, September 2020)